Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program.
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...
Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (Keytruda) in the KeyVibe programme. Favezelimab is being evaluated as an investigational fixed-dose ...
In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of ...
New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...
Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...
Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...
Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.
The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ®, together with ...
An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback